Odyssey Therapeutics reports additional Phase 2a clinical data for its investigational treatment, OD-001, in ulcerative colitis. The company’s update is based on information presented at UEG Week, according to the sources.
Both outlets describe the company sharing new trial results for the Phase 2a program, but they do not present a full unified set of endpoints or detailed numbers in the excerpts provided. One source frames the update as part of a presentation transcript from UEG Week, while the other characterizes it more generally as “Phase 2a ulcerative colitis trial data.” Overall, the coverage centers on the timing (UEG Week) and the indication (ulcerative colitis), with the additional data meant to inform ongoing evaluation of OD-001’s performance in the study.
The articles focus on what Odyssey Therapeutics is communicating publicly about the Phase 2a trial, rather than including independent analysis or regulatory decisions in the provided text.